Cancer/Tumor Profiling
Cancer/Tumor Profiling Market by Technology (Immunoassays, In-Situ Hybridization, Mass Spectrometry), Biomarker Type (Genomic Biomarker, Protein Biomarker), Cancer Type, Application - Global Forecast 2024-2030
360iResearch Analyst
SPEAK TO ANALYST? OR FACE-TO-FACE MEETING?
Want to know more about the cancer/tumor profiling market or any specific requirement? Ketan helps you find what you're looking for.
DOWNLOAD A FREE PDF
This free PDF includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.

[182 Pages Report] The Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023 and expected to reach USD 12.77 billion in 2024, at a CAGR 18.74% to reach USD 35.94 billion by 2030.

Cancer/tumor profiling is a laboratory method that analyzes specific proteins, genes, and other molecules in a tumor to provide information about any genetic or molecular changes, such as gene mutations. Tumor profiling is the technology that oncologists widely use to determine if the pathways of a patient’s tumor match up with available targeted treatments. Accelerated use of biomarkers in the treatment of cancer patients and increasing preference for customized cancer treatments coupled with government and international organization's efforts to develop cancer diagnosis methods support the widespread use of cancer/tumor profiling technologies. On the other hand, high capital investment in cancer/tumor profiling tools and services and low biomarker discovery-to-approval ratio hinders market development. However, the spread of next-generation sequencing, tumor profiling improvements, and point-of-care cancer detection technology expansion is expected to surge their use in the coming years.

Regional Insights

Cancer/tumor profiling market landscape in North America, the EU, GCC, and developed countries across the Asia-Pacific region are highly advanced due to prominent market players and well-established regulatory frameworks and initiatives launched by the governments to reduce cancer burden while improving patient care. Cancer profiling is gradually gaining prominence in developing economies worldwide as investments in cancer diagnostics continue to rise. According to the American Cancer Society, approximately 1.9 million new cancer cases are anticipated to be diagnosed in the United States in 2023, bolstering the need for cancer profiling. Northern and Western European countries observe considerably high use and availability of biomarker testing procedures, reflecting their higher investment in healthcare. Market players across countries are collaborating with technology providers in the United States and European countries and each other to contribute to deploying the advancement in cancer diagnosis, profiling, and treatment procedures. Furthermore, the ongoing campaigns and cancer awareness programs have highlighted the need for cancer/tumor profiling in Asian countries.

Cancer/Tumor Profiling Market
To learn more about this report, request a free PDF copy
Market Dynamics

The market dynamics represent an ever-changing landscape of the Cancer/Tumor Profiling Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Increasing adoption of biomarkers to treat cancer patients
    • Availability of government and global organizations' initiatives for devising cancer diagnosing methods
    • Surging preference for personalized medicines for cancer treatment
  • Market Restraints
    • High capital investment in cancer/tumor profiling instruments and services
  • Market Opportunities
    • Emergence of next-generation sequencing and advancements in tumor profiling
    • Improvements in point-of-care diagnostic technologies to improve cancer detection
  • Market Challenges
    • Low biomarker discovery-to-approval ratio
Market Segmentation Analysis
  • Technology: Adoption of next-generation sequencing (NGS) for exploring genetic alterations in various cancers

    Immunoassays dominate the technology segment of the cancer tumor profiling market owing to rising applications in conducting tumor profiling on a large scale, as they aid in measuring the presence and concentration of analytes in a sample. In situ hybridization (ISH), including fluorescence in-situ hybridization (FISH) and chromogenic in situ hybridization (CISH), uses labeled complementary DNA or RNA strands to localize a specific DNA or RNA sequence on a chromosome or section of tissue (in-situ) fixed on a slide. FISH profiling is less time-consuming than conventional approaches and assists in easy chromosomal microdeletion, amplification, and translocation. Mass spectrometry-based cancer/tumor profiling is increasingly used in cancer research to detect subtle changes in proteome and metabolome. In contrast, microarrays are widely used to understand cancer cells' genetic and epigenetic makeup, and they are utilized to identify small genetic changes in tumor cells. The development of next-generation sequencing (NGS) helps in effectively exploring genetic alterations in various cancers and identifying several genetic or epigenetic variants to develop new biomarkers for early diagnosis of the disease. Polymerase chain reaction (PCR) is used to look for specific changes in a gene or chromosome, which helps find and diagnose a genetic condition or a disease, such as cancer. Moreover, technological advances in imaging and biochemical processes that allow earlier detection of a metastatic lesion could yield higher success rates in cancer therapy.

  • Biomarker Type: Use of genomic biomarkers for the measurement of the expression of a gene, the gene function, and the gene regulation

    Genomic biomarkers can be termed as the measurement of the expression of a gene, the gene function, or the gene regulation, and testing can determine whether someone's cancer has an estimated glomerular filtration rate (EGFR) gene mutation that can be treated with an EGFR inhibitor and also helps study a new cancer treatment in a clinical trial. An ideal cancer biomarker can be a protein or protein fragment that is easy to detect in the patient's blood or urine except for a healthy patient. In addition, there are many cancer biomarkers, and they separately work within the body and react differently to treatments. These cancer biomarkers can also include gene mutations (changes), gene rearrangements, extra copies of genes, missing genes, and several other molecules.

  • Cancer Type: Wide preference for cancer profiling in prostate cancers for predictive modeling and clinical risk stratification

    Cancer/tumor profiling has become an integral part of disease management on multiple levels for breast cancer. Genetic testing identifies hereditary cancer syndromes in patients with a family history of malignancies and contributes to successful breast cancer prevention. Molecular profiling of colorectal cancer (CRC) has the advantage of providing essential information on the pathogenesis of cancer and also about the targeted therapy. The landscape of metastatic CRC (mCRC) treatment is changing with an understanding of its heterogeneity and molecular blueprint, although chemotherapy remains the backbone of treatment. Common genetic mutations in lung cancer, such as estimated glomerular filtration rate (EGFR), RET, MET, BRAF, and anaplastic lymphoma kinase (ALK), can be detected, which leads to offering targeted therapy to the patient. Molecular predictive tests based on gene expression profiling (GEP) of cutaneous melanoma (CM) are susceptible and have the potential to predict biological behavior. Moreover, cancer/tumor profiling of prostate cancer has more recently emerged as a reliable method for predictive modeling and clinical risk stratification. Integrative genomic profiling of prostate tumors has provided comprehensive information and novel discoveries that improve understanding of the disease in the new era of precision medicine.

  • Application: Increasing use of cancer/tumor profiling in developing precision medicine to improve healing and recovery time

    Cancer/tumor profiling has significantly advanced clinical oncology by identifying therapeutic targets and molecular biomarkers, guiding the personalization of cancer treatment with remarkably improved outcomes for numerous common and rare tumor entities. Cancer/tumor profiling is normally used in developing precision medicine that suits a patient's genetic makeup to improve healing and recovery time. The upgradation of biomarker discovery and development with the application of new and complex technologies and more clinical applications of biomarkers improves diagnosis, prognosis, and disease monitoring. Researchers are touting more precision-based and targeted techniques to streamline cancer treatment, which propels rapid diagnostics providers to seek highly sophisticated cancer profiling approaches. Genome-based prognostic biomarkers are used in the prognosis of several cancer types at clinical stages and also help develop drugs and therapies. Cancer/tumor profiling is also helpful in cancer screening and can help in early detection, management, and, potentially, curing cancer. In addition, cancer/tumor profiling offers the sensitive and accurate detection of biomarkers and has a reliable approach for noninvasive disease diagnosis and treatment response monitoring.

Market Disruption Analysis

The market disruption analysis delves into the core elements associated with market-influencing changes, including breakthrough technological advancements that introduce novel features, integration capabilities, regulatory shifts that could drive or restrain market growth, and the emergence of innovative market players challenging traditional paradigms. This analysis facilitates a competitive advantage by preparing players in the Cancer/Tumor Profiling Market to pre-emptively adapt to these market-influencing changes, enhances risk management by early identification of threats, informs calculated investment decisions, and drives innovation toward areas with the highest demand in the Cancer/Tumor Profiling Market.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Cancer/Tumor Profiling Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

Value Chain & Critical Path Analysis

The value chain of the Cancer/Tumor Profiling Market encompasses all intermediate value addition activities, including raw materials used, product inception, and final delivery, aiding in identifying competitive advantages and improvement areas. Critical path analysis of the <> market identifies task sequences crucial for timely project completion, aiding resource allocation and bottleneck identification. Value chain and critical path analysis methods optimize efficiency, improve quality, enhance competitiveness, and increase profitability. Value chain analysis targets production inefficiencies, and critical path analysis ensures project timeliness. These analyses facilitate businesses in making informed decisions, responding to market demands swiftly, and achieving sustainable growth by optimizing operations and maximizing resource utilization.

Pricing Analysis

The pricing analysis comprehensively evaluates how a product or service is priced within the Cancer/Tumor Profiling Market. This evaluation encompasses various factors that impact the price of a product, including production costs, competition, demand, customer value perception, and changing margins. An essential aspect of this analysis is understanding price elasticity, which measures how sensitive the market for a product is to its price change. It provides insight into competitive pricing strategies, enabling businesses to position their products advantageously in the Cancer/Tumor Profiling Market.

Technology Analysis

The technology analysis involves evaluating the current and emerging technologies relevant to a specific industry or market. This analysis includes breakthrough trends across the value chain that directly define the future course of long-term profitability and overall advancement in the Cancer/Tumor Profiling Market.

Patent Analysis

The patent analysis involves evaluating patent filing trends, assessing patent ownership, analyzing the legal status and compliance, and collecting competitive intelligence from patents within the Cancer/Tumor Profiling Market and its parent industry. Analyzing the ownership of patents, assessing their legal status, and interpreting the patents to gather insights into competitors' technology strategies assist businesses in strategizing and optimizing product positioning and investment decisions.

Trade Analysis

The trade analysis of the Cancer/Tumor Profiling Market explores the complex interplay of import and export activities, emphasizing the critical role played by key trading nations. This analysis identifies geographical discrepancies in trade flows, offering a deep insight into regional disparities to identify geographic areas suitable for market expansion. A detailed analysis of the regulatory landscape focuses on tariffs, taxes, and customs procedures that significantly determine international trade flows. This analysis is crucial for understanding the overarching legal framework that businesses must navigate.

Regulatory Framework Analysis

The regulatory framework analysis for the Cancer/Tumor Profiling Market is essential for ensuring legal compliance, managing risks, shaping business strategies, fostering innovation, protecting consumers, accessing markets, maintaining reputation, and managing stakeholder relations. Regulatory frameworks shape business strategies and expansion initiatives, guiding informed decision-making processes. Furthermore, this analysis uncovers avenues for innovation within existing regulations or by advocating for regulatory changes to foster innovation.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Cancer/Tumor Profiling Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Cancer/Tumor Profiling Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Agilent and NCCS Sign Research Collaboration Agreement to Advance Singapore's Genomic Profiling on Asian-prevalent Cancers

    Agilent Technologies Inc. has entered into a Research Collaboration Agreement (RCA) with the National Cancer Centre Singapore to accelerate translational cancer research on Asian-prevalent cancers over the next two years. As part of this agreement, Agilent has supplied an automated NGS library preparation platform, enabling investigations into the genomic details specific to Asian cancer cohorts. [Published On: 2023-09-19]

  • Sophia Genetics, Agilent Partner on Cancer Analysis Product

    Sophia Genetics, a leader in data-driven medicine, has recently announced a long-term partnership with Agilent Technologies, allowing them to develop a new cancer analysis product. This new product will enable clinicians to use patient’s genomic profiling information for smarter and more efficient care decisions. Through this endeavor, both companies are working towards making personalized cancer treatments faster and more accessible. With their product, doctors can move from the traditional trial-and-error approach of prescribing drugs to one tailored and precisely matches therapeutic agents to the tumor's genetics. The longer-term research is underway as well, which could help serve as an important resource for future cancer studies. [Published On: 2023-03-14]

  • Point32Health and Foundation Medicine Expand Access to Comprehensive Genomic Profiling for Members with Advanced Cancer

    Point32Health and Foundation Medicine have recently taken a major step forward in providing comprehensive genomic profiling for members with advanced cancer. By expanding access to this technology, individuals will now receive tailored treatments that can increase their chances of responding to the therapy needed for successful treatment outcomes. This initiative will increase human-recoded data levels and provide a more personalized approach to cancer treatments, leading the way in providing the best possible care for those fighting the disease. With Foundation Medicine's mission to accelerate precision medicine and Point32Health's dedication to making complex molecular information accessible, these two organizations are positioned as game changers when advancing cancer treatments. [Published On: 2023-03-02]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Cancer/Tumor Profiling Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Cancer/Tumor Profiling Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, ACT Genomics Co., Ltd. by Prenetics Global Limited, Agendia, Inc., Agilent Technologies, Inc., BostonGene Corporation, Caris Life Sciences, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GENINUS Inc., Genomic Life, GenScript Biotech Corporation, Guardant Health, Inc., Hologic, Inc., HTG Molecular Diagnostics, Inc., Illumina, Inc., IMBdx, Inc., Laboratory Corporation of America Holdings, Lucence Health, Inc., Merck KGaA, NanoString Technologies, Inc., Neogenomics, Inc., Nonacus Limited, OncoDNA S.A., Oncompass Medicine Hungary Kft., Paragon Genomics, Inc., Personalis, Inc., Perthera, Inc., Predictive Oncology Inc., Strand Life Sciences, Sysmex Corporation, Takara Bio Inc., Tempus Labs Inc., and Thermo Fisher Scientific Inc..

Cancer/Tumor Profiling Market - Global Forecast 2024-2030
To learn more about this report, request a free PDF copy
Market Segmentation & Coverage

This research report categorizes the Cancer/Tumor Profiling Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Immunoassays
    • In-Situ Hybridization
    • Mass Spectrometry
    • Microarrays
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Biomarker Type
    • Genomic Biomarker
    • Protein Biomarker
  • Cancer Type
    • Breast Cancer
    • Colorectal Cancer
    • Lung Cancer
    • Melanoma Cancer
    • Prostate Cancer
  • Application
    • Biomarker Discovery
    • Clinical Application
    • Diagnostics
    • Personalized Medicine
    • Prognostics
    • Research
    • Screening
    • Treatment & Monitoring

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Cancer/Tumor Profiling Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Cancer/Tumor Profiling Market, by Technology
  7. Cancer/Tumor Profiling Market, by Biomarker Type
  8. Cancer/Tumor Profiling Market, by Cancer Type
  9. Cancer/Tumor Profiling Market, by Application
  10. Americas Cancer/Tumor Profiling Market
  11. Asia-Pacific Cancer/Tumor Profiling Market
  12. Europe, Middle East & Africa Cancer/Tumor Profiling Market
  13. Competitive Landscape
  14. Competitive Portfolio
  15. List of Figures [Total: 24]
  16. List of Tables [Total: 394]
  17. List of Companies Mentioned [Total: 33]
Tumor Profiling: Enhancing Diagnosis and Personalized Cancer Care
June 19, 2023
BLOG
Tumor Profiling: Enhancing Diagnosis and Personalized Cancer Care
Cancer remains a pervasive global health problem, affecting millions of people worldwide. Despite advances in cancer treatment, the diagnosis and management of various types of cancers still encounter several limitations. However, the recent proliferation of next-generation sequencing (NGS) technologies has revolutionized the field of oncology, leading to the development of tumor profiling as a tool for cancer diagnosis and personalized treatment. This blog post takes a closer look at how tumor profiling is enhancing cancer care and improving patient outcomes.

What is Tumor Profiling?

Tumor profiling is a method of analyzing the genetic, epigenetic, and protein alterations in a tumor. This process helps define molecular targets for therapy, identify potential biomarkers for diagnosis, and monitor disease progression. The primary technology used for tumor profiling is next-generation sequencing (NGS), which provides an in-depth characterization of the genomic landscape of a tumor. NGS techniques are more sensitive and comprehensive in detecting genomic alterations when compared to traditional diagnostic methods, which rely on microscopic examination.

Advancements in Tumor Profiling:

Advancements in tumor profiling have led to the development of new cancer therapies such as immunotherapies, targeted therapies, and combination therapies. Molecular profiling identifies the molecular characteristics of an individual's cancer, and this information can help clinicians select the most effective therapy for the respective patient. The use of NGS in tumor profiling has allowed clinicians to observe genomic alterations in a tumor, which permits for tailored treatment of each patient. The analysis of the tumor's genomic sequencing allows us to tailor our treatments for the patient's specific cancer and identify therapies that have the greatest possibility of success.

Challenges Associated with Tumor Profiling:

Despite the many benefits of tumor profiling, there are still some obstacles clinicians need to address. Interpreting the vast volumes of data generated from genomic sequencing is challenging and requires the expertise of specialists such as bioinformaticians. Another issue is the variation seen in the methods of profiling used in different cancer centers. Growing tumor profiling involves centralizing the genetic data of each patient to a Registry, allowing for a more comprehensive analysis of genomic variations across a broader population. The sharing of data across cancer centers in real-time permits Collaboration among clinicians and researchers in search of better treatments.

Emerging Uses of Tumor Profiling:

Tumor profiling has the potential to benefit cancer patients in multiple ways. One such way is predicting the risk of cancer recurrence. Some studies have demonstrated that genomic profiling of tumors in an early stage of the disease predicts the probability of tumor recurrence. Besides, tumor profiling can also serve as a tool for predicting a patient's response to various cancer therapies. Researchers are pursuing new possibilities for utilizing tumor samples to determine which treatments may be most beneficial.

Future Implications of Tumor Profiling:

Tumor profiling has created the possibility for a more individualized approach toward cancer care. Precision medicine aims to tailor cancer treatments unique to each patient by analyzing the alterations in their tumor's genomic sequencing. The data generated from tumor profiling analysis will likely continue to play a vital role in shaping cancer care approaches of the future. The growth of genetic knowledge will allow cancer research to develop new, innovative, and efficient drugs. As these studies continue, we need to ensure access to molecular profiling testing and promote research that furthers our understanding of the cancer genome.

The advancement of cancer profiling by next-generation sequencing (NGS) techniques has revolutionized cancer diagnosis and treatment. Tumor profiling provides clinicians with a more comprehensive understanding of a patient's cancer. This understanding assists in diagnosis, identifies suitable therapies, and helps monitor the progression of the disease. Moving forward, tumor profiling will undoubtedly prove to be a crucial tool in the treatment of cancer, and efforts to make molecular diagnostic testing more available will increase the precision of cancer diagnosis and treatment.

Frequently Asked Questions
  1. How big is the Cancer/Tumor Profiling Market?
    Ans. The Global Cancer/Tumor Profiling Market size was estimated at USD 10.79 billion in 2023 and expected to reach USD 12.77 billion in 2024.
  2. What is the Cancer/Tumor Profiling Market growth?
    Ans. The Global Cancer/Tumor Profiling Market to grow USD 35.94 billion by 2030, at a CAGR of 18.74%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.